Valeo Pharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Al Moghaddam

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.6yrs
Board average tenure1.8yrs

Recent management updates

Recent updates


CEO

Al Moghaddam (57 yo)

less than a year

Tenure

Mr. Al Moghaddam, B. Com. CMA had been a Director at Valeo Pharma Inc. since March 21, 2024 until June 2024 and served as its Chief Development Officer since June 2024 until August 2024 and serves as its C...


Leadership Team

NamePositionTenureCompensationOwnership
Kyle Steiger
Senior VP & Chief Commercial Officer2.3yrsCA$388.21k0.020%
$ 909.4
Al Moghaddam
Chief Executive Officerless than a yearno datano data
Pascal Tougas
Chief Financial Officerless than a yearno datano data
Frédéric Dumais
Director of Communications & Investor Relationsno datano data0.26%
$ 12.1k
Guy-Paul Allard
VP of Legal Affairs & Corporate Secretaryno datano data0%
$ 0
Jean Fournier
Head of Ophthalmology Business Unit2.3yrsno datano data

1.6yrs

Average Tenure

Experienced Management: VPHI.F's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Robert Raich
Independent Directorless than a yearno data0.18%
$ 8.2k
Richard MacKay
Chairman of the Advisory Board & Director15.8yrsno data16.44%
$ 760.8k
Steven Saviuk
Chairman21.7yrsCA$466.29k0.18%
$ 8.5k
Marc Leger
Independent Non-Executive Director2.6yrsno data2.36%
$ 109.3k
Richard Lajoie
Independent Directorless than a yearno datano data
Charles Bisaillon
Independent Directorless than a yearno datano data

1.8yrs

Average Tenure

65yo

Average Age

Experienced Board: VPHI.F's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/26 04:15
End of Day Share Price 2024/08/29 00:00
Earnings2024/07/31
Annual Earnings2023/10/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Valeo Pharma Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Neil LinsdelliA Capital Markets
Chelsea StellickiA Capital Markets
Scott McAuleyParadigm Capital, Inc.